Insect-mediated pollination in slickspot peppergrass, Lepidium papilliferum L. (Brassicaceae), and its implications for population viability

Field experiments on the pollination biology of slickspot peppergrass, Lepidium papilliferum L. (Brassicaceae), a rare species endemic to microsites in sagebrush-steppe habitat in southwestern Idaho, were conducted at 2 sites from May to July 2001. Site KB contained over 10,000 plants, whereas site WG contained less than 150 plants. Insect exclusion experiments revealed that seed production in L. papilliferum is dependent on insect-mediated pollination; median percent seed set dropped from 70% to 2% when insects were excluded from flowers. A total of 25 insect families from 5 orders visited L. papilliferum flowers: 24 families at KB and 11 families at WG. Only 9 families contained more than trace amounts of pollen on their bodies: Hymenoptera-Anthophoridae, Apidae, Colletidae, Halictidae, Sphecidae, Vespidae; Coleoptera-Cerambycidae, Dermestidae; Diptera-Syrphidae. Insects from these families are likely responsible for pollination of L. papilliferum , although some may be of only minor significance due to their infrequent visits to flowers. Two of the 4 most common and pollen-laden insects found at KB, honey bees ( Apis mellifera ) and colletid bees, were absent or rare at WG. Three other pollen-carrying families present at KB, Sphecidae, Vespidae, and Halictidae, were not found at WG. We raise several possible explanations for this disparity in pollinator communities between sites and discuss the importance of pollinator diversity to the long term viability of L. papilliferum .     

Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans

The efficacy and safety of biological molecules in cancer therapy, such as peptides and small interfering RNAs (siRNAs), could be markedly increased if high concentrations could be achieved and amplified selectively in tumour tissues versus normal tissues after intravenous administration. This has not been achievable so far in humans. We hypothesized that a poxvirus, which evolved for blood-borne systemic spread in mammals, could be engineered for cancer-selective replication and used as a vehicle for the intravenous delivery and expression of transgenes in tumours. JX-594 is an oncolytic poxvirus engineered for replication, transgene expression and amplification in cancer cells harbouring activation of the epidermal growth factor receptor (EGFR)/Ras pathway, followed by cell lysis and anticancer immunity. Here we show in a clinical trial that JX-594 selectively infects, replicates and expresses transgene products in cancer tissue after intravenous infusion, in a dose-related fashion. Normal tissues were not affected clinically. This platform technology opens up the possibility of multifunctional products that selectively express high concentrations of several complementary therapeutic and imaging molecules in metastatic solid tumours in humans.